191 related articles for article (PubMed ID: 17986636)
1. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Courtney R; Stewart PM; Toh M; Ndongo MN; Calle RA; Hirshberg B
J Clin Endocrinol Metab; 2008 Feb; 93(2):550-6. PubMed ID: 17986636
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.
Bhat BG; Hosea N; Fanjul A; Herrera J; Chapman J; Thalacker F; Stewart PM; Rejto PA
J Pharmacol Exp Ther; 2008 Jan; 324(1):299-305. PubMed ID: 17921190
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
[TBL] [Abstract][Full Text] [Related]
5. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.
Siu M; Johnson TO; Wang Y; Nair SK; Taylor WD; Cripps SJ; Matthews JJ; Edwards MP; Pauly TA; Ermolieff J; Castro A; Hosea NA; LaPaglia A; Fanjul AN; Vogel JE
Bioorg Med Chem Lett; 2009 Jul; 19(13):3493-7. PubMed ID: 19473839
[TBL] [Abstract][Full Text] [Related]
6. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Rosenstock J; Banarer S; Fonseca VA; Inzucchi SE; Sun W; Yao W; Hollis G; Flores R; Levy R; Williams WV; Seckl JR; Huber R;
Diabetes Care; 2010 Jul; 33(7):1516-22. PubMed ID: 20413513
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH; Stone JA; Crumley TM; Wenning L; Zheng W; Yan K; Yang AY; Sun L; Cilissen C; Ramael S; Hermanowski-Vosatka A; Langdon RB; Gottesdiener KM; Wagner JA; Lai E
Br J Clin Pharmacol; 2013 Dec; 76(6):917-31. PubMed ID: 23594227
[TBL] [Abstract][Full Text] [Related]
8. Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Stewart PM; Boulton A; Kumar S; Clark PM; Shackleton CH
J Clin Endocrinol Metab; 1999 Mar; 84(3):1022-7. PubMed ID: 10084590
[TBL] [Abstract][Full Text] [Related]
9. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
Finken MJ; Andrews RC; Andrew R; Walker BR
J Clin Endocrinol Metab; 1999 Sep; 84(9):3316-21. PubMed ID: 10487705
[TBL] [Abstract][Full Text] [Related]
10. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.
Moore JS; Monson JP; Kaltsas G; Putignano P; Wood PJ; Sheppard MC; Besser GM; Taylor NF; Stewart PM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4172-7. PubMed ID: 10566668
[TBL] [Abstract][Full Text] [Related]
11. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
12. A simple LC-MS/MS method for the determination of cortisol, cortisone and tetrahydro-metabolites in human urine: assay development, validation and application in depression patients.
Zhai X; Chen F; Zhu C; Lu Y
J Pharm Biomed Anal; 2015 Mar; 107():450-5. PubMed ID: 25668797
[TBL] [Abstract][Full Text] [Related]
13. Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus.
Anderson AJ; Andrew R; Homer NZ; Jones GC; Smith K; Livingstone DE; Walker BR; Stimson RH
J Clin Endocrinol Metab; 2016 Oct; 101(10):3787-3793. PubMed ID: 27459533
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S; Nordaby M; Plum-Mörschel L; Peil B; Heise T
Diabetes Obes Metab; 2023 Mar; 25(3):832-843. PubMed ID: 36478142
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.
Andersson T; Simonyte K; Andrew R; Strand M; Burén J; Walker BR; Mattsson C; Olsson T
PLoS One; 2009 Dec; 4(12):e8475. PubMed ID: 20041117
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxysteroid dehydrogenase activity in the brain does not contribute to systemic interconversion of cortisol and cortisone in healthy men.
Kilgour AH; Semple S; Marshall I; Andrews P; Andrew R; Walker BR
J Clin Endocrinol Metab; 2015 Feb; 100(2):483-9. PubMed ID: 25393644
[TBL] [Abstract][Full Text] [Related]
17. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
Espiard S; McQueen J; Sherlock M; Ragnarsson O; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Skrtic S; Wahlberg J; Stewart PM; Johannsson G
J Clin Endocrinol Metab; 2021 Mar; 106(3):814-825. PubMed ID: 33236103
[TBL] [Abstract][Full Text] [Related]
18. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
Gelding SV; Taylor NF; Wood PJ; Noonan K; Weaver JU; Wood DF; Monson JP
Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
[TBL] [Abstract][Full Text] [Related]
19. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
Harno E; White A
Trends Endocrinol Metab; 2010 Oct; 21(10):619-27. PubMed ID: 20594868
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol.
Andrew R; Smith K; Jones GC; Walker BR
J Clin Endocrinol Metab; 2002 Jan; 87(1):277-85. PubMed ID: 11788660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
